Research programme: neuronal nitric oxide synthase inhibitors - Akava Therapeutics/Northwestern University
Alternative Names: nNOS inhibitors - Akava TherapeuticsLatest Information Update: 26 Apr 2023
Price :
$50 *
At a glance
- Originator Northwest University
- Class Antidementias; Antineoplastics; Antiparkinsonians; Small molecules
- Mechanism of Action Nitric oxide synthase type I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Cerebral palsy; Malignant melanoma; Parkinson's disease
Most Recent Events
- 05 Apr 2023 Preclinical trials in Alzheimer's disease in USA (PO) as of April 2023 (Akava Therapeutics pipeline, April 2023)
- 05 Apr 2023 Preclinical trials in Cerebral palsy in USA (PO) as of April 2023 (Akava Therapeutics pipeline, April 2023)
- 05 Apr 2023 Preclinical trials in Malignant melanoma in USA (PO) as of April 2023 (Akava Therapeutics pipeline, April 2023)